GNMX - Cerecor inks CERC-002 licensing deal with Kyowa Kirin shares up 6%

Cerecor's (CERC) wholly-owned subsidiary, Aevi Genomic Medicine (GNMX) has entered into an expanded agreement with Kyowa Kirin (KYKOF), for exclusive worldwide rights to develop, manufacture and commercialize CERC-002 monoclonal antibody for all indications. Under the terms of agreement, Kyowa Kirin will receive an up-front payment from Cerecor and is also eligible to receive additional milestone payments, as well as sales-based royalties and a share of sublicensing income. Kyowa Kirin has an option to retain the rights in Japan. CERC-002 is a fully human anti-LIGHT or tumor necrosis factor superfamily member 14 (TNFSF14) monoclonal antibody licensed from Kyowa Kirin.It is the only clinical stage anti-LIGHT therapy and has the potential to treat a number of LIGHT-associated immune diseases including cytokine storm-induced COVID-19 ARDS.CERC-002 is currently in development for pediatric onset Crohn’s disease and cytokine storm induced COVID-19 ARDS.

For further details see:

Cerecor inks CERC-002 licensing deal with Kyowa Kirin, shares up 6%